Efficacy of intravenous immunoglobulin treatment in immunocompromised children with H1N1 influenza: a clinical observation

Basit Öğe Kaydı
dc.contributor.authorGokturk, Bahar
dc.contributor.authorPekcan, Sevgi
dc.contributor.authorGuner, Sukru Nail
dc.contributor.authorArtac, Hasibe
dc.contributor.authorKeles, Sevgi
dc.contributor.authorKirac, Mine
dc.contributor.authorReisli, Ismail
dc.date.accessioned2024-02-23T14:24:03Z
dc.date.available2024-02-23T14:24:03Z
dc.date.issued2016
dc.departmentNEÜen_US
dc.description.abstractBackground and AimsThe appropriate treatment of pandemic H1N1 influenza which was first identified in April 2009 in Mexico is insufficient especially for immunocompromised patients. We aimed to evaluate the features and prognostic factors of the children with H1N1, especially immunocompromised ones, and whether intravenous immunoglobulin G (IVIG) replacement could aid for a better outcome. MethodsTwenty-one hospitalized children with laboratory-confirmed H1N1 were evaluated retrospectively. Data were extracted from files and electronic medical records. ResultsThe median age was 37 (1-216) months; 62% of them were under 5years of age and 71.4% had one or more underlying disorders. Main symptoms were high fever, cough, fatigue and vomiting. Lower respiratory tract manifestations were seen in 66.6% of children. Mortality rate was 4.7%. The patient who died had the lowest lymphocyte (100/mm(3)), thrombocyte (21000/mm(3)) and highest blood urea nitrogen (87mg/dL) levels. Fifty-eight percent of evaluated patients had one of the primary immunodeficiency disorders. Surprisingly, none of the six patients with primary immunodeficiency who are on regular IVIG replacement needed intensive care unit and died. Although median durations of cough, fever and hospitalization were lower, they did not change statistically according to get IVIG replacement regularly (P=0.47, 0.97, 0.09, respectively). ConclusionOur study is important while it is the first one that shows the course of primary immunodeficient children with H1N1 infection who were on regular IVIG replacement. A trial of high-dose IVIG may be a useful adjunctive therapy in severe H1N1 influenza, particularly in the immunocompromised patients.en_US
dc.identifier.doi10.1111/crj.12209
dc.identifier.endpage230en_US
dc.identifier.issn1752-6981
dc.identifier.issn1752-699X
dc.identifier.issue2en_US
dc.identifier.pmid25196245en_US
dc.identifier.scopus2-s2.0-84959264477en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage223en_US
dc.identifier.urihttps://doi.org/10.1111/crj.12209
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13802
dc.identifier.volume10en_US
dc.identifier.wosWOS:000372001600013en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofClinical Respiratory Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChilden_US
dc.subjectH1n1 Influenzaen_US
dc.subjectImmunodeficiencyen_US
dc.subjectIntravenous Immunoglobulin Gen_US
dc.titleEfficacy of intravenous immunoglobulin treatment in immunocompromised children with H1N1 influenza: a clinical observationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu